Crispr Therapeutics (NASDAQ:CRSP) Upgraded at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a hold rating to a buy rating in a report issued on Saturday morning, BidAskClub reports.

A number of other research firms also recently issued reports on CRSP. Barclays raised their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a research note on Tuesday, July 30th. BTIG Research raised their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a positive rating in a research note on Tuesday, July 30th. Evercore ISI began coverage on Crispr Therapeutics in a research note on Thursday, April 11th. They issued an outperform rating on the stock. Canaccord Genuity began coverage on Crispr Therapeutics in a research note on Friday, July 26th. They issued a buy rating and a $72.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Crispr Therapeutics in a research note on Thursday, August 1st. They issued a buy rating and a $64.00 price target on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $58.00.

CRSP stock opened at $45.00 on Friday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $59.00. The company has a current ratio of 13.96, a quick ratio of 13.96 and a debt-to-equity ratio of 0.10. The business has a fifty day moving average price of $48.24.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, July 29th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.84). The firm had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $47.57 million. Crispr Therapeutics had a negative return on equity of 51.49% and a negative net margin of 15,136.56%. The business’s quarterly revenue was down 70.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.82) earnings per share. On average, equities research analysts expect that Crispr Therapeutics will post -3.86 earnings per share for the current fiscal year.

In related news, President Rodger Novak sold 50,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $45.00, for a total value of $2,250,000.00. Following the transaction, the president now directly owns 898,007 shares of the company’s stock, valued at approximately $40,410,315. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Lawrence Otto Klein sold 20,000 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $50.02, for a total value of $1,000,400.00. Following the completion of the transaction, the insider now directly owns 31,579 shares in the company, valued at $1,579,581.58. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 140,000 shares of company stock worth $6,670,400. 21.40% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Valeo Financial Advisors LLC raised its holdings in Crispr Therapeutics by 71.4% during the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after acquiring an additional 302 shares during the period. Flagship Harbor Advisors LLC raised its holdings in Crispr Therapeutics by 22.1% during the first quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock valued at $118,000 after acquiring an additional 600 shares during the period. Creative Planning raised its holdings in Crispr Therapeutics by 4.7% during the first quarter. Creative Planning now owns 15,486 shares of the company’s stock valued at $553,000 after acquiring an additional 695 shares during the period. BNP Paribas Arbitrage SA bought a new stake in Crispr Therapeutics during the second quarter valued at about $41,000. Finally, Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after acquiring an additional 986 shares during the period. 51.71% of the stock is currently owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Why do companies pay special dividends?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp


© 2006-2019 Ticker Report